Mobile

A study to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals’ investigational vaccine GSK2838504A when administered to chronic obstructive pulmonary disease (COPD) ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-003062-13

A study to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals’ investigational vaccine GSK2838504A when administered to chronic obstructive pulmonary disease (COPD) patients with persistent airflow obstruction

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To describe the safety and reactogenicity of the investigational vaccine

Critère d'inclusion

  • COPD

Liens